Article info
PDFEditorial commentary
Antineuronal antibodies and epilepsy: treat the patient, not the lab
- Correspondence to Dr Stephan Rüegg, Medical Faculty, University of Basel, Basel 4031, Switzerland; S.Rueegg{at}unibas.ch
Citation
Antineuronal antibodies and epilepsy: treat the patient, not the lab
Publication history
- Received November 24, 2020
- Accepted November 25, 2020
- First published January 5, 2021.
Online issue publication
February 12, 2021
Article Versions
- Previous version (12 February 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.